Bioinvent International Ab · OMXSTO:BINV
Bioinvent International Ab — Q3 2025 Earnings Presentation
24 slides from Bioinvent International Ab's earnings presentation, Oct 29, 2025
Slide 1: Interim Report Q3, 2025
Q3.25 bringing antibodies to life INTERIM REPORT Q3, 2025 AI-generated image showing how the immune system can attack a cancer tumor Martin Welschof, CEO: “The third quarter of 2025 marked continued momentum for BioInvent as we EXPECTED KEY CATALYSTS decided to focus on our most advanced programs BI
Slide 2: Highlights Q3, 2025
HIGHLIGHTS Highlights Q3, 2025 EVENTS IN THE THIRD QUARTER • Strategic changes in portfolio to accelerate lead clinical programs and enhance value creation • (R) Changes to the Board; Vincent Ossipow stepped down EVENTS AFTER THE END OF THE PERIOD • Phase 2a trial with BI-1206 in combination with pe
Slide 3: Doubling down on our most promising assets
COMMENTS BY THE CEO Doubling down on our most promising assets The third quarter of 2025 marked continued momentum for BioInvent as we decided to focus on our most advanced programs BI-1206 and BI-1808, two first in class assets with activity in liquid and solid cancer with upcoming near to mid-term
Slide 4: Expected key clinical milestones 2025/2026
COMMENTS BY THE CEO In Phase 1, BI-1206 demonstrated favorable safety and percent of evaluable patients achieving disease control and 45 LOOKING AHEAD promising clinical activity in heavily pre-treated patients. Since percent demonstrating objective responses accompanied by We continue to execute on
Slide 5: Sharp focus to maximize clinical and commercial success of lead programs
FINANCIALPROGRAMS CLINICAL INFORMATION Sharp focus to maximize BioInvent is developing novel immuno-modulatory antibodies for cancer therapy. These innovative antibodies may clinical and commercial significantly improve the efficacy of currently available checkpoint inhibitors and/or activate anti-c
Slide 6: BI-1808 targeting TNFR2
FINANCIALPROGRAMS CLINICAL INFORMATION BI-1808 DISCOVERY Selection of drug TARGETING TNFR2 BioInvent’s anti-TNFR2 antibody BI-1808 is a first-in-class drug candidate in clinical development for the candidate treatment of solid tumors and for T-cell lymphoma. In the ongoing Phase 1/2a study, BI-1808
Slide 7: BI-1206 in non-Hodgkin's lymphoma
FINANCIALPROGRAMS CLINICAL INFORMATION BI-1206 in non-Hodgkin’s lymphoma DISCOVERY Selection of drug TARGETING FCyRIIB FcyRIIB is overexpressed in several forms of NHL and overexpression has been associated with poor prognosis candidate in difficult-to-treat forms of NHL, such as mantle cell lymphom
Slide 8: Out-licensing and partnering
FINANCIALPROGRAMS CLINICAL INFORMATION evaluate the pharmacokinetic profile, select the dose for OUT-LICENSING AND PARTNERING Phase 2 and assess early signs of clinical efficacy as part of In February 2024, a clinical supply agreement was signed with its development program for BI-1206 in China and
Slide 9: BI-1206 in solid tumors
FINANCIALPROGRAMS CLINICAL INFORMATION BI-1206 in solid tumors DISCOVERY Selection of drug TARGETING FCyRIIB The ongoing clinical program addresses the ability of BI-1206 to target an important mechanism of candidate resistance to PD-1 inhibition, providing a way to enhance anti-tumor immune respons
Slide 10: Strategic collaborations
FINANCIAL INFORMATION COLLABORATION AND LICENSING AGREEMENTS Strategic collaborations BioInvent collaborates with a number of important players within the pharmaceutical industry and within academia. The collaborations with other pharmaceutical companies focus on commercial partnerships for BioInven
Slide 11: BT-001 targeting CTLA-4
FINANCIALPROGRAMS CLINICAL INFORMATION – COLLABORATIONS BT-001 DISCOVERY Selection of drug TARGETING CTLA-4 BT-001 is an oncolytic virus armed with BioInvent’s anti-CTLA-4 antibody. When the virus is infecting the candidate tumor cells it releases the anti-CTLA-4 locally in the tumor to decrease the
Slide 12: Discovery and preclinical development
FINANCIAL INFORMATION DISCOVERY AND PRECLINICAL DEVELOPMENT Discovery and preclinical development BioInvent’s discovery and preclinical research is focused on developing novel immuno-modulatory antibodies for cancer therapy. Such antibodies may significantly improve efficacy of currently available c
Slide 13: Financial information
FINANCIAL INFORMATION Financial information REVENUES AND RESULT Revenues for the corresponding period 2024 were mainly PARENT COMPANY Figures in parentheses refer to the outcome for the derived from production of antibodies for clinical studies and The main operations of the Group are conducted by t
Slide 14: Consolidated statement of comprehensive income in brief for the Group
FINANCIAL INFORMATION Consolidated statement of comprehensive income in brief for the Group (SEK thousand) 3 MONTHS 3 MONTHS 9 MONTHS 9 MONTHS 12 MONTHS 2025 2024 2025 2024 2024 JULY-SEP. JULY-SEP. JAN.-SEP. JAN.-SEP. JAN.-DEC. Net sales 3,321 12,764 223,479 23,317 44,686 Operating costs Research an
Slide 15: Consolidated statement of financial position in brief for the Group
FINANCIAL INFORMATION Consolidated statement of financial position in brief for the Group (SEK thousand) 2025 2024 2024 SEP. 30 SEP. 30 DEC. 31 ASSETS Intangible fixed assets 0 0 0 Tangible fixed assets - leases 11,585 17,017 17,720 Tangible fixed assets - other 25,399 30,406 28,302 Financial fixed
Slide 16: Statement of changes in equity for the Group
FINANCIAL INFORMATION Statement of changes in equity for the Group (SEK thousand) 2025 2024 2025 2024 2024 JULY-SEP. JULY-SEP. JAN.-SEP. JAN.-SEP. JAN.-DEC. Shareholders’ equity at beginning of period 810,744 1,097,516 885,815 1,309,727 1,309,727 Comprehensive income Profit/loss -129,223 -97,242 -20
Slide 17: Consolidated statement of cash flows in brief for the Group
FINANCIAL INFORMATION Consolidated statement of cash flows in brief for the Group (SEK thousand) 2025 2024 2025 2024 2024 JULY-SEP. JULY-SEP. JAN.-SEP. JAN.-SEP. JAN.-DEC. Operating activities Operating profit/loss -133,606 -107,146 -222,272 -345,186 -471,059 Depreciation 4,812 4,832 15,019 14,424 1
Slide 18: Key financial ratios for the Group
FINANCIAL INFORMATION Key financial ratios for the Group 2025 2024 2024 SEP. 30 SEP. 30 DEC. 31 Shareholders’ equity per share at end of period, SEK 10.38 15.24 13.46 Number of shares at end of period (thousand) 65,804 65,804 65,804 Equity/assets ratio, % 86.9 92.2 89.5 Number of employees at end of
Slide 19: Consolidated income statement in brief for the Parent Company
FINANCIAL INFORMATION Consolidated income statement in brief for the Parent Company (SEK thousand) 3 MONTHS 3 MONTHS 9 MONTHS 9 MONTHS 12 MONTHS 2025 2024 2025 2024 2024 JULY-SEP. JULY-SEP. JAN.-SEP. JAN.-SEP. JAN.-DEC. Net sales 3,321 12,764 223,479 23,317 44,686 Operating costs Research and develo
Slide 20: Consolidated balance sheet in brief for the Parent Company
FINANCIAL INFORMATION Consolidated balance sheet in brief for the Parent Company (SEK thousand) 2025 2024 2024 SEP. 30 SEP. 30 DEC. 31 ASSETS Intangible fixed assets 0 0 0 Tangible fixed assets 25,399 30,406 28,302 Financial fixed assets - Shares in subsidiaries 1,008 687 687 Financial fixed assets
Slide 21: Review report
FINANCIAL INFORMATION Review report INTRODUCTION We have reviewed the summarized interim financial information (interim report) for BioInvent International AB (publ) on September 30, 2025 and for the nine-month period then ended. The board of directors and the CEO are responsible for the preparation
Slide 22: Information notes
FINANCIAL INFORMATION Information notes NOTE 1 ACCOUNTING PRINCIPLES Except for leases, the Group’s and the Parent Company’s NOTE 3 EVENTS AFTER THE REPORTING PERIOD This interim report in brief for the Group has been prepared financial statements coincide in every material way. • Phase 2a trial sta
Slide 23: Other information
FINANCIAL OTHER INFORMATION INFORMATION Other information ANNUAL GENERAL MEETING CONTACT FORWARD LOOKING INFORMATION The Annual General Meeting will be held on April 29, 2026, at 4 Any questions regarding this report will be answered by This interim report contains statements about the future, p.m.
Slide 24: Interview with Dr. Andres McAllister, BioInvent CMO
Interview with Dr. Andres McAllister, BioInvent CMO In this interview, originally published by Biostock, Dr. Andres enhances the anti-tumor response, potentially converting non- HOW HAS THE COLLABORATION WITH MSD CONTRIBUTED McAllister, CMO at BioInvent, provides an in-depth description of responder
BioInvent International — Q3 2025 Earnings Presentation on 6ix